Day 1 - Thursday, 29 November 2018
RespiDART 2018
Enduring Materials
- 15:00
15:00
Opening remarks
Session 1: Respiratory viruses: Global trends and current challenges -
Chairs
Matthias Götte, MSc, PhD
University of Alberta, Canada
Kirsty Short, PhD
University of Queensland, Australia & Erasmus MC, the Netherlands
15:15
Keynote lecture: Current challenges, regulatory considerations, and emerging viruses
Ralph Baric, PhD
University of North Carolina, USA
15:45
Plenary Lecture: Opportunities and Challenges for a Broadly Protective Influenza Vaccine
Session 2: Therapeutics against respiratory viruses: Clinical advances & industry perspective (Non-CME session) -
Chairs
Gary Nabel, MD
Sanofi, USA
16:25
Baloxavir is a first-in-class oral cap-dependent endonuclease inhibitor for treatment of influenza: overview of pre-clinical, phase I and II trials
Takeki Uehara, PhD
Shionogi, Japan
16:45
Baloxavir is effective and well tolerated in treating otherwise-healthy and high-risk influenza patients: overview of phase III trials
Andrew Ackrill, PhD
Roche, UK
18:05
End of Day 1
Day 2 - Friday, 30 November 2018
Session 3: Basic science, enzymology and respiratory virus inhibition strategies -
Chairs
Masaru Kanekiyo, PhD
NIH, USA
Charles Boucher, MD, PhD
Erasmus Medical Center, The Netherlands
9:00
State-of-the-art lecture: Enzymology of RSV and influenza RdRp
Matthias Götte, MSc, PhD
University of Alberta, Canada
9:50
Respiratory Syncytial Virus Binds to a Signaling Coreceptor which Induces Recruitment of its Receptor, Nucleolin, to the Cell Surface during Entry
David Marchant, PhD
University of Alberta, Canada
Session 4: New study models and complications beyond acute respiratory infection -
Chairs
David Marchant, PhD
University of Alberta, Canada
Rachel Fearns, PhD
Boston University School of Medicine, USA
10:40
State-of-the-art lecture: Respiratory tract infections and chronic conditions: The case for influenza and diabetes
Kirsty Short, PhD
University of Queensland, Australia & Erasmus MC, the Netherlands
11:30
SB 9200 is a novel broad-spectrum antiviral agent effective against both RSV and Flu (#101)
11:40
Structure-based prediction of influenza resistance mutations (#102)
11:50
Risk factors for RSV severity in immunocompetent and immunocompromised adults presenting in an emergency department (#103)
12:00
Evaluation of the therapeutic potential of antibody and T cell targeted immune responses towards RSV small hydrophobic protein (#105)
12:10
Panel Discussion
Session 5: Immunology and advances in vaccine development -
Chairs
Ralph Baric, PhD
University of North Carolina, USA
Asuncion Mejias, PhD
The Research Institute At Nationwide Children’s Hospital, USA
16:00
Plenary Lecture: Respiratory syncytial virus pathogenesis & special pediatric populations
Asuncion Mejias, PhD
The Research Institute At Nationwide Children’s Hospital, USA
16:30
Nanoparticle display of influenza antigens for development of a universal influenza vaccine
Masaru Kanekiyo, PhD
NIH, USA
16:50
Advances in vaccine development against Respiratory Syncytial Virus
Martin Moore, PhD
Meissa Vaccines, USA
17:10
Non-targeted diagnosis of multiple viral infections by means of shotgun metagenomic using deep sequencing (#104)
17:20
mRNA vaccines expressing forms of RSV-F protein are immunogenic and protective in preclinical models of respiratory syncytial virus infection (#106)
Amy Espeseth, PhD
Merck, USA
17:30
Panel Discussion
17:45
Concluding remarks
18:00
End of Workshop
Overview
Welcome
We would like to thank you for joining us for RespiDART in Miami, Florida! We hope you enjoyed your time in Miami, and look forward to seeing you for the next edition. We will take your feedback on the frequency and location into account to help us determine when and where the 2nd edition will take place.
We would like to take this opportunity to thank the RFS Family Foundation, Roche, Monogram Biosciences, the NIH, Genentech, and Merck for making this event possible and supporting us in making this first edition a success.
If you would like to stay in touch with us and hear about our upcoming meetings, please sign-up for our newsletter.
Thank you for your participation!
Committees
Organizing Committee
The members of the Organizing Committee (OC) are a group of carefully selected experts and inspirational leaders in their respective fields. They come together on a frequent basis to discuss the scientific program of the workshop, identify interesting topics and candidate speakers and review all submitted abstracts.
Peter Palese, PhD
Icahn School of Medicine at Mount Sinai, USA
Scientific Committee
The members of Scientific Committee assist the Organizing Committee by providing them with suggestions for speakers and topics. In addition, members of the Scientific Committee participate in reviewing submitted abstracts, and play an active role during the workshop as moderators and/or chairs of sessions.
- Ralph Baric, PhD - Gillings School of Global Public Health, Chapel Hill, USA
- Larry Blatt, PhD - Aligos Biopharma, San Francisco, CA, USA
- Christian Brechot, PhD, MD - Global virus network, Baltimore, MD, USA
- Matthias Gotte, PhD - University of Alberta, Edmonton, AB, Canada
- David Marchant, PhD - University of Alberta, Edmonton, AB, Canada
- Asuncion Mejias, PhD - The Research Institute at Nationwide Children's Hospital, OH, USA
- Christos Petropoulos, PhD - LabCorp, San Francisco, USA
- Kenneth Powell, PhD - ReViral, Stevenage, UK
- Debbie van Riel, PhD - Erasmus Medical Center, The Netherlands
Support
Endorsers
